shows the cases averted in Fig.3 , along with the corresponding numbers of tests consumed to acquire these levels of coverage. For the latter, the transmission model only counts cases of TB, but to account for the overall amount of Xpert testing needed, it is necessary also to account for TB-negative suspects receiving Xpert testing. In particular, the demonstration data suggests that roughly 24% of suspects receiving an Xpert test are diagnosed as having TB; amongst MDR risk groups, this figure is 87%.
To estimate the total number of Xpert tests corresponding to a given coverage, we therefore divide the modelled number of TB diagnoses by a factor of 0.24 (under universal access) and a factor of 0.87 (when targeting MDR risk-groups). A simple calculation, this gives indicative numbers for the scale of Xpert deployment involved, and may be an underestimate: a more in-depth analysis would, for example, account more systematically for how these ratios may change over time, with changes in incidence and prevalence. 
Pre-careseeking stages
Uninfected cases: depletion by infection, and replenishment by population turnoveṙ
where λ htrsp is the 'force of infection' arising from infectious cases of types h, t, r, s, p, namely:
with infectious terms on the right-hand side defined in the following, remaining equations.
Latent infections without treatment historẏ
Latent infections with treatment historẏ
Active disease, pre-careseeking, without treatment historẏ
Active disease, pre-careseeking, with treatment historẏ
Diagnosis-seeking stages
Patient consulting provider in sector p, awaiting diagnosis without Xperṫ
Patient consulting provider in sector p, awaiting diagnosis with Xperṫ
Patient diagnosed as having TB (includes patients with unknown MDR status -also see equ.(17) for patients failing to be diagnosed altogether)
Patient diagnosed as having MDR-TB -either upfront through Xpert, or subsequently through followup (conventional) DST (applies only to subscript r = 1)
Treatment stages
Patient on first-line treatment, without followup DST (laboratory culture, or LPA): negative terms refer respectively to default (δ p ); de-novo acquisition of multi-drug-resistance (a rp -assumed zero if the patient already has MDR-TB); followup DST owing to non-response to treatment (f ); first-line treatment completion (τ 1 ); and death (µ hs ).
Patient on first-line treatment, pending results from followup DST (laboratory culture, or LPA): the last term on the right-hand-side denotes cases identified as MDR-TB (entering class D (4) , above).
Patient on second-line treatment:
Cure and between-careseeking stages
Cure from first-line treatment (noting subscript t = 1 on the left-hand-side to denote individuals having treatment history):Ċ
( 1) h,1,rs = ωy rp T
(1) 
Cure from second-line treatment:
h,1,1,s = ωy T 
Self-cureĊ 
Between care-seeking episodes: patients failing to be diagnosed, or who have defaulted from treatment:
htrsp + δ p T
(1) htrsp + T
htrsp − (c + µ hs )B htrs (17)
